MEK inhibitors

One of the first projects between the firms will be to develop and commercialize a companion diagnostic for the MEK inhibitor binimetinib in NRAS-mutant melanoma.

Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.

"Seeing that we have had other agents in this class, there should be some sort of selection of tumor types, or some type of genomic profiling, or at least retainment of archival tissue, so that we can go on to profile these patients at a later date," said Patricia LoRusso of Karmanos Cancer Institute at Wayne State University, who reviewed early dosing trials of three MEK inhibitors being developed by GlaxoSmithKline, Merck Serono, and Eisai.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.